AbbVie price target raised to $172 from $167 at BofA

BofA raised the firm’s price target on AbbVie to $172 from $167 and keeps a Neutral rating on the shares. The firm said the ImmunoGen deal’s early closure has improved AbbVie’s near-term growth outlook, as it added Elahere sales earlier than expected.